Therapeutic Benefits of Selenium in Hematological Malignancies

Int J Mol Sci. 2022 Jul 19;23(14):7972. doi: 10.3390/ijms23147972.

Abstract

Supplementing chemotherapy and radiotherapy with selenium has been shown to have benefits against various cancers. This approach has also been shown to alleviate the side effects associated with standard cancer therapies and improve the quality of life in patients. In addition, selenium levels in patients have been correlated with various cancers and have served as a diagnostic marker to track the efficiency of treatments or to determine whether these selenium levels cause or are a result of the disease. This concise review presents a survey of the selenium-based literature, with a focus on hematological malignancies, to demonstrate the significant impact of selenium in different cancers. The anti-cancer mechanisms and signaling pathways regulated by selenium, which impart its efficacious properties, are discussed. An outlook into the relationship between selenium and cancer is highlighted to guide future cancer therapy development.

Keywords: cancer; chemoprevention; chemotherapeutic; hematologic malignancies; leukemia; murine disease model; radiotherapy; selenium; selenoprotein.

Publication types

  • Review

MeSH terms

  • Hematologic Neoplasms* / drug therapy
  • Humans
  • Neoplasms* / drug therapy
  • Quality of Life
  • Selenium* / metabolism

Substances

  • Selenium

Grants and funding

This research was partially supported by the funds from National Institutes of Health (NIH) under the National Cancer Institute (P01CA171983).